These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31514107)

  • 1. Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
    de Jong EEC; Sanders KJC; Deist TM; van Elmpt W; Jochems A; van Timmeren JE; Leijenaar RTH; Degens JHRJ; Schols AMWJ; Dingemans AC; Lambin P
    Eur J Cancer; 2019 Oct; 120():107-113. PubMed ID: 31514107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.
    Dingemans AM; Groen HJ; Herder GJ; Stigt JA; Smit EF; Bahce I; Burgers JA; van den Borne BE; Biesma B; Vincent A; van der Noort V; Aerts JG;
    Ann Oncol; 2015 Nov; 26(11):2286-93. PubMed ID: 26347109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
    Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC
    Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
    Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
    Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
    Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
    Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
    Cong M; Feng H; Ren JL; Xu Q; Cong L; Hou Z; Wang YY; Shi G
    Lung Cancer; 2020 Jan; 139():73-79. PubMed ID: 31743889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients.
    Sugai Y; Kadoya N; Tanaka S; Tanabe S; Umeda M; Yamamoto T; Takeda K; Dobashi S; Ohashi H; Takeda K; Jingu K
    Radiat Oncol; 2021 Apr; 16(1):80. PubMed ID: 33931085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.
    Zhu X; Dong D; Chen Z; Fang M; Zhang L; Song J; Yu D; Zang Y; Liu Z; Shi J; Tian J
    Eur Radiol; 2018 Jul; 28(7):2772-2778. PubMed ID: 29450713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Yamasaki M; Murakami I; Nakano K; Doi M; Kitaguchi S; Kondo T; Sakurai J; Hattori N; Arita KI
    Anticancer Res; 2017 Feb; 37(2):923-928. PubMed ID: 28179353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.
    Coroller TP; Agrawal V; Huynh E; Narayan V; Lee SW; Mak RH; Aerts HJWL
    J Thorac Oncol; 2017 Mar; 12(3):467-476. PubMed ID: 27903462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
    Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J
    J Clin Oncol; 2001 Jan; 19(2):442-7. PubMed ID: 11208837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer.
    Ding T; Li ZT; Zhang X; Shi YT
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3723-3729. PubMed ID: 28925468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.